Tseng L F, Collins K A
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee.
J Pharmacol Exp Ther. 1992 Mar;260(3):1086-92.
The effects of sulfated cholecystokinin octapeptide (CCK8s) given intrathecally (i.t.) or intracerebroventricularly (i.c.v.) on inhibition of the tail-flick and paw-licking hot-plate responses induced by beta-endorphin, morphine, D-Ala2-N-Me-Phe4-Gly-ol-Enkephalin (DAMGO) and D-Pen2-D-Pen5-Enkephalin (DPDPE), given i.t. or i.c.v., were studied in male ICR mice. CCK8s (1 ng) given i.t. effectively antagonized inhibition of the tail-flick response induced by i.c.v. administered beta-endorphin (2 micrograms) and DPDPE (10 micrograms) but not morphine (4 micrograms) or DAMGO (0.02 microgram). However, CCK8s given i.t. did not affect inhibition of the hot-plate response induced by any of the opioid agonists. CCK8s (0.2-40 ng) in combination with beta-endorphin (2 micrograms) or morphine (4 micrograms) given i.c.v. did not affect beta-endorphin- or morphine-induced inhibition of the tail-flick and hot-plate responses. CCK8s and its fragments given i.t. attenuated i.c.v. beta-endorphin-induced tail-flick inhibition with different potencies and efficacies. CCK8s was the most potent compound in antagonizing i.c.v. beta-endorphin-induced tail-flick inhibition. The rank order of potencies was CCK8s greater than CCK(27-33) much greater than caerulein. All three compounds were efficacious, whereas CCK(30-33) was not, in antagonizing beta-endorphin-induced tail-flick inhibition. Intrathecal administration of CCK8s (1 ng) significantly attenuated the tail-flick inhibition induced by i.t. beta-endorphin (0.5-1 microgram) and DPDPE (5 micrograms) but not morphine (0.5-1 microgram), DAMGO (5 ng), norepinephrine (5 ng) or serotonin (16 micrograms).(ABSTRACT TRUNCATED AT 250 WORDS)
在雄性ICR小鼠中,研究了鞘内注射(i.t.)或脑室内注射(i.c.v.)硫酸化胆囊收缩素八肽(CCK8s)对i.t.或i.c.v.给予的β-内啡肽、吗啡、D-丙氨酸2-N-甲基苯丙氨酸4-甘氨酸-ol-脑啡肽(DAMGO)和D-青霉胺2-D-青霉胺5-脑啡肽(DPDPE)诱导的甩尾和舔足热板反应抑制的影响。鞘内注射1 ng CCK8s可有效拮抗脑室内注射2 μgβ-内啡肽和10 μg DPDPE诱导的甩尾反应抑制,但不能拮抗4 μg吗啡或0.02 μg DAMGO诱导的抑制。然而,鞘内注射CCK8s不影响任何阿片类激动剂诱导的热板反应抑制。脑室内注射0.2 - 40 ng CCK8s与2 μgβ-内啡肽或4 μg吗啡联合使用,不影响β-内啡肽或吗啡诱导的甩尾和热板反应抑制。鞘内注射CCK8s及其片段以不同的效价和效力减弱脑室内β-内啡肽诱导的甩尾抑制。CCK8s是拮抗脑室内β-内啡肽诱导的甩尾抑制最有效的化合物。效价顺序为CCK8s大于CCK(27 - 33)远大于蛙皮素。在拮抗β-内啡肽诱导的甩尾抑制方面,所有三种化合物均有效,而CCK(30 - 33)无效。鞘内注射1 ng CCK8s可显著减弱鞘内注射0.5 - 1 μgβ-内啡肽和5 μg DPDPE诱导的甩尾抑制,但不能减弱0.5 - 1 μg吗啡、5 ng DAMGO、5 ng去甲肾上腺素或16 μg 5-羟色胺诱导的抑制。(摘要截短至250字)